42-30 CHMP Issues Positive Opinion for Onivyde Combination in Pancreatic Adenocarcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Drugs and Targets

CHMP Issues Positive Opinion for Onivyde Combination in Pancreatic Adenocarcinoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending marketing authorization of Onivyde (irinotecan liposome injection, nal-IRI), in combination with 5-fluorouracil and leucovorin, for the treatment of metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine based therapy.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login